KA
KALA.US Kala Pharmaceuticals Inc
- Market cap
- USD 89.5K
- P/E
- -
- P/B
- 0.30x
- ROE
- -70.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is KALA.US undervalued?
Graham numberThe Graham number of Kala Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kala Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Kala Pharmaceuticals Inc yet.
Kala Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kala Pharmaceuticals Inc
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC…
Full company profileKala Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kala Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 6.07M | 6.36M | 11.2M | 3.89M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -297K | -643K | -955K | 3.23M | 3.19M | 7.14M | 1.33M | -303K | -259K | -317K | - |
| Operating Income | -32.7M | -39.9M | -64.7M | -88.2M | -96.2M | -109M | -81.4M | -39.2M | -40.4M | -39.2M | -7.05M |
| EBITDA | -32.4M | -39.2M | -63.8M | -87.4M | -95.3M | -133M | -37.0M | -36.1M | -32.5M | -23.4M | -6.40M |
| Net Income | -33.2M | -42.2M | -66.7M | -94.3M | -104M | -143M | -44.8M | -42.2M | -38.5M | -27.0M | -6.40M |
| EPS | -96 | -99 | -125 | -138 | -100 | -108 | -1,474 | -868 | -507 | -166 | -86 |
| Balance Sheet | |||||||||||
| Total Assets | 46.3M | 116M | 221M | 154M | 222M | 139M | 86.8M | 55.9M | 55.5M | 9.49M | 10.6M |
| Total Liabilities | 134M | 26.5M | 116M | 125M | 122M | 123M | 67.8M | 48.4M | 43.2M | 2.49M | 1.54M |
| Shareholders' Equity | -87.8M | 89.7M | 105M | 29.7M | 100.0M | 16.8M | 19.0M | 7.50M | 12.3M | 7.00M | 9.04M |
| Cash & Short-term Investments | 45.5M | 115M | 171M | 85.4M | 154M | 92.1M | 70.5M | 50.9M | 51.2M | 7.56M | 7.23M |
| Total Debt | 9.65M | 18.7M | 99.4M | 101M | 101M | 80.2M | 43.0M | 36.3M | 32.3M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -27.3M | -34.1M | -54.1M | -92.7M | -90.7M | -108M | -78.9M | -27.9M | -29.4M | -32.0M | -8.86M |
| Capital Expenditure | 153K | 480K | 1.58M | 1.34M | 1.94M | 886K | 313K | 610K | 208K | 15.0K | 32.0K |
| Free Cash Flow | -27.5M | -34.6M | -55.7M | -94.1M | -92.6M | -109M | -79.2M | -28.5M | -29.6M | -32.0M | -8.86M |
| Ratios | |||||||||||
| ROE | - | -47.1% | -63.6% | -317.8% | -104.3% | -848.6% | -236.2% | -562.4% | -312.3% | -385.6% | -70.8% |
| ROA | -71.6% | -36.3% | -30.2% | -61.1% | -47.1% | -102.3% | -51.6% | -75.4% | -69.4% | -284.3% | -60.5% |
| Net Profit Margin | - | - | - | -1,553.3% | -1,639.8% | -1,268.7% | -1,151.6% | - | - | - | - |
| Debt to Equity | - | 0.21x | 0.95x | 3.41x | 1.01x | 4.77x | 2.26x | 4.84x | 2.62x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kala Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 365K | 7.50 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:30 on Nov 16, 2026.
Who owns Kala Pharmaceuticals Inc
- Insiders 6.25%
- Institutions 4.59%
- Public & others 89.16%
- Shares outstanding 645K
- Free float 19.3M
Top funds holding KALA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 95.8K | 0.50% | -0.21% | Sep 2026 |
| Fidelity Series Total Market Index | 25.5K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 23.3K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 12.8K | 0.07% | 0.00% | Aug 2026 |
Top institutions holding KALA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 221K | 1.14% | +18,118.25% | Jun 2026 |
| Geode Capital Management, LLC | 145K | 0.75% | +2,680.16% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 101K | 0.52% | +16,998.82% | Jun 2026 |
| State Street Corp | 88.6K | 0.46% | +15,384.27% | Jun 2026 |
| Renaissance Technologies Corp | 81.1K | 0.42% | 0.00% | Sep 2026 |
| BlackRock Inc | 71.5K | 0.37% | +33,021.30% | Jun 2026 |
| Northern Trust Corp | 41.6K | 0.22% | +17,989.57% | Jun 2026 |
| Qube Research & Technologies | 11.1K | 0.06% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 10.9K | 0.06% | +3,786.48% | Jun 2026 |
| UBS Group AG | 9.06K | 0.05% | +577.41% | Jun 2026 |
| Tower Research Capital LLC | 616.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 608.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 28.00 | 0.00% | -52.54% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 10.00 | 0.00% | 0.00% | Jun 2026 |
| International Assets Investment Management, LLC | 2.00 | 0.00% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Steward Partners Investment Advisory, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citadel Advisors Llc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| GSA Capital Partners LLP | 0.00 | 0.00% | -100.00% | Jun 2026 |
| SBI Securities Co Ltd | 0.00 | 0.00% | 0.00% | Jun 2026 |
Kala Pharmaceuticals Inc company profile
- Company name
- Kala Pharmaceuticals Inc
- Ticker
- KALA.US
- Exchange
- USA Stocks
- Listed since
- Jul 20, 2017
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 6
- Fiscal year end
- December
- Address
- 1167 Massachusetts Avenue, Arlington, MA, United States, 02476
- Phone
- 781 996 5252
- Website
- kalarx.com
About Kala Pharmaceuticals Inc
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Kala Pharmaceuticals Inc management
9- Ms. Mary Reumuth CPATreasurer & Secretary · born 1975
- Mr. Avi MinkowitzCEO, CFO & Chairman · born 1988
- Dr. Justin Hanes Ph.D.Founder & Chair of the Scientific Advisory Board
- Ms. Jill S. SteierExecutive Director of Investor Relations & Corporate Communications
- Mr. Vincent KosewskiSenior VP of Manufacturing & Supply Chain Management · born 1963
- Dr. Francis S. Mah M.D.Chief Medical Advisor
- Mr. Josiah Craver CPASenior VP & Corporate Controller
- Mr. Carl RennieExecutive Director of Account Management
- Mr. Patrick BedellExecutive Director of Trade & Alternate Channels